Clinical Scorecard: Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial
At a Glance
| Category | Detail |
|---|---|
| Condition | Primary Progressive Multiple Sclerosis (PPMS) |
| Key Mechanisms | Bruton’s tyrosine kinase (BTK) inhibition |
| Target Population | Adults with primary progressive multiple sclerosis |
| Care Setting | Clinical trial setting |
Key Highlights
- Fenebrutinib met primary endpoint in head-to-head study against OCREVUS.
- Demonstrated a 12% reduction in risk of disability progression compared to OCREVUS.
- Strongest treatment effect observed in upper limb function, reducing risk by 26%.
- Safety profile comparable between fenebrutinib and OCREVUS.
- Fenebrutinib could be the first oral therapy to reduce disability progression in PPMS.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of PPMS should be confirmed using clinical criteria and MRI findings.
Management
- Consider fenebrutinib as a treatment option for patients with PPMS.
Monitoring & Follow-up
- Monitor for adverse events, particularly liver enzyme elevations and infections.
Risks
- Common adverse events include infections, nausea, and transient liver enzyme elevations.
Patient & Prescribing Data
Adults with primary progressive multiple sclerosis.
Fenebrutinib shows consistent clinical benefits, especially in upper limb function.
Clinical Best Practices
- Assess functional disability using EDSS, timed 25-foot walk, and nine-hole peg test.
- Evaluate treatment effects across patient subgroups.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
